Equisin 25 mg FC tablets
PDF Leaflet Revision Date: 10 July 2023
Clinical Summary
Quick overview from the medicine insert
Indication
Advanced oestrogen receptor positive breast cancer in postmenopausal women.
Dosage (summary)
25 mg once daily after a meal.
Special Populations
- Hepatic impairment
- Renal impairment
Pregnancy & Breastfeeding
Contraindicated in pregnancy and lactation.
Key Drug Interactions
- CYP3A4 inducers
- Oestrogen-containing medicines
Contraindications
- Hypersensitivity to exemestane
- Pre-menopausal women
- Pregnant or lactating women
Common side effects
- Hot flushes
- Arthralgia
- Fatigue
- Nausea
Counselling Points
- Monitor bone mineral density
- Discuss contraception with women of childbearing potential
Serious warnings
- Reductions in bone mineral density
- Increased fracture rate
Important Disclaimer
The Equisin 25 mg FC tablets professional information leaflet below is the property of Equity Pharmaceuticals and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
